Organon (OGN) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Organon (OGN) closed at $12.20 in the latest trading session, marking a +0.66% move from the prior day. The stock trailed the S&P 500, which registered a daily gain of 0.74%. Elsewhere, the Dow ...

Organon has acquired regulatory and commercial rights in the United States from Biogen for Tofidence, a biosimilar to Actemra for intravenous infusion. Tofidence, the first approved tocilizumab ...

Organon pays up to $1.2B to acquire Dermavant and its steroid-free skin cream Vtama Women’s health drugmaker Organon is also initiating New Jersey layoffs, to the tune of 93 staffers in Jersey ...

Organon (OGN) closed at $11.30 in the latest trading session, marking a +1.07% move from the prior day. The stock exceeded the S&P 500, which registered a gain of 0.79% for the day. Elsewhere, the ...

Organon & Co (Symbol: OGN) presently has a stellar rank, in the top 10% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors.

Organon acquired regulatory and commercial rights in the United States for TOFIDENCE ™, a biosimilar to ACTEMRA ®, for intravenous infusion from Biogen. TOFIDENCE, the first approved ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Organon (OGN – Research Report), with a price target of $15.00. The company’s shares closed last ...

Organon (OGN) announced that it has acquired from Biogen (BIIB) regulatory and commercial rights in the U.S. for Tofidence, a biosimilar to Actemra, for intravenous infusion. Tofidence, the first ...

Organon & Co. has a 1-year low of $12.15 and a 1-year high of $23.10. The company has a market cap of $3.23 billion, a PE ratio of 3.76, a price-to-earnings-growth ratio of 0.90 and a beta of 0.73.